Bausch Health/$BHC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Ticker
$BHC
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Laval, Canada
Employees
20,700
ISIN
CA0717341071
Website
Bausch Health Metrics
BasicAdvanced
$2.4B
-
-$0.11
0.43
-
Price and volume
Market cap
$2.4B
Beta
0.43
52-week high
$9.49
52-week low
$3.96
Average daily volume
2.5M
Financial strength
Current ratio
1.347
Quick ratio
0.753
Long term debt to equity
-8,845
Total debt to equity
-6,782.298
Interest coverage (TTM)
1.36%
Profitability
EBITDA (TTM)
3,089
Gross margin (TTM)
70.78%
Net profit margin (TTM)
-0.41%
Operating margin (TTM)
19.08%
Effective tax rate (TTM)
142.86%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
4.31%
Return on equity (TTM)
39.13%
Valuation
Price to revenue (TTM)
0.243
Price to book
-2.02
Price to tangible book (TTM)
-0.14
Price to free cash flow (TTM)
1.965
Free cash flow yield (TTM)
50.90%
Free cash flow per share (TTM)
329.81%
Growth
Revenue change (TTM)
8.53%
Earnings per share change (TTM)
-91.28%
3-year revenue growth (CAGR)
5.34%
10-year revenue growth (CAGR)
1.38%
3-year earnings per share growth (CAGR)
-54.22%
10-year earnings per share growth (CAGR)
-28.04%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Bulls say / Bears say
Bausch Health reported its eighth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth, with a 6% and 14% increase respectively, indicating strong operational performance. (biospace.com)
The company successfully completed a $7.9 billion refinancing in April 2025, extending near- and medium-term maturities, which enhances financial stability. (biospace.com)
Director John Paulson increased his stake by purchasing 3,564,059 shares in June 2025, reflecting insider confidence in the company's prospects. (marketbeat.com)
Bausch Health's total debt stood at $22 billion as of Q1 2024, with a leverage ratio of 6.7 times, raising concerns about financial flexibility. (investing.com)
The company's key revenue driver, Xifaxan®, faces price negotiations under the Inflation Reduction Act in 2027, potentially impacting future revenues. (panabee.com)
Unverified reports in July 2024 suggested Bausch Health was negotiating a prepackaged Chapter 11 bankruptcy filing to address its debt issues, causing significant stock volatility. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Bausch Health News
AllArticlesVideos
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Accesswire·1 week ago
Bausch Health Appoints New Chief Accounting Officer
Accesswire·1 week ago
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch Health stock?
Bausch Health (BHC) has a market cap of $2.4B as of July 18, 2025.
What is the P/E ratio for Bausch Health stock?
The price to earnings (P/E) ratio for Bausch Health (BHC) stock is 0 as of July 18, 2025.
Does Bausch Health stock pay dividends?
No, Bausch Health (BHC) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Bausch Health dividend payment date?
Bausch Health (BHC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch Health?
Bausch Health (BHC) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.